Alaunos Therapeutics, Inc.

Alaunos Therapeutics, Inc.

Alaunos Therapeutics was founded in 2015 as a spin-out from ZIOPHARM Oncology, later incorporating as a standalone public company (NASDAQ: TCRT). Kevin S. Boyle, Sr. has served as CEO since 2020, steering the firm toward a proprietary library of TCR therapies. The firm's wealth origin is tied to public equity markets rather than private family capital, though its shareholder base includes institutional investors and retail holders. The company's strategy centers on a library of 1,775 TCR sequences targeting 63 distinct antigens, primarily in solid tumors such as non-small cell lung cancer (NSCLC) and pancreatic cancer. Its clinical-stage assets include the Phase 1/2 trial for Alaunos' TCR-T therapy in patients with NSCLC, conducted at The University of Texas MD Anderson Cancer Center. The firm also holds a license to the Sleeping Beauty transposon platform, a non-viral gene delivery system for T-cell engineering. Geographically, operations are concentrated in Houston, Texas, with research collaborations extending to academic institutions across the United States. Alaunos employs approximately 30 staff as of late 2023, per SEC filings. The firm has not disclosed total deployment figures, but its operational budget is constrained by cash reserves—$35.3 million as of Q3 2023 (per SEC filing, November 2023). The company maintains a single office in Houston and has no publicly known additional offices. No adjacent philanthropic vehicles or club memberships are reported. A structural differentiator is Alaunos' Sleeping Beauty platform, a non-viral approach to generating TCR-T cells, which may reduce manufacturing complexity compared to viral vectors. This technology, originally developed at MD Anderson, positions the firm as a platform-based entrant rather than solely a drug developer. However, the firm's lack of near-term commercialization and dependency on public capital markets differentiates it from typical family-office entities in its sector.